You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,143,379


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,143,379
Title:Human monoclonal antibodies to CTLA-4
Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
Inventor(s): Hanson; Douglas Charles (Niantic, CT), Neveu; Mark Joseph (Hartford, CT), Mueller; Eileen Elliott (Old Lyme, CT), Hanke; Jeffrey Herbert (Reading, MA), Gilman; Steven Christopher (Cambridge, MA), Davis; C. Geoffrey (Burlingame, CA), Corvalan; Jose Ramon (Foster City, CA)
Assignee: Amgen Fremont Inc. (Fremont, CA) Pfizer Inc. (New York, NY)
Application Number:11/981,824
Patent Claims:1. A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to CTLA-4, wherein said antibody comprises a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino acid residues 13-22, 37-51, and 86-94 of SEQ ID NO: 8; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino acid residues 19-29, 45-51, and 83-92 of SEQ ID NO: 21.

2. A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CTLA-4, wherein the light chain variable domain of said antibody comprises the amino acid sequence in SEQ ID NO: 21.

3. A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CTLA-4, wherein the heavy chain variable domain of said antibody comprises the amino acid sequence in SEQ ID NO: 8.

4. The monoclonal antibody or antigen-binding portion according to claim 2, wherein the light chain variable domain of said antibody comprises the amino acid sequence in SEQ ID NO: 21 and the heavy chain variable domain of said antibody comprises the amino acid sequence in SEQ ID NO: 8.

5. A human monoclonal antibody or an antigen-binding portion thereof, wherein said antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain and the CDR1, CDR2, and CDR3 of the light chain of the antibody produced by hybridoma 4.13.1.1 having American Type Culture Collection (ATCC) accession number PTA-5167.

6. The antibody or antigen-binding portion according to claim 5, wherein said antibody has the heavy and light chain amino acid sequences of the antibody produced by said hybridoma.

7. The antibody or antigen-binding portion according to claim 1 that is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody.

8. The antibody or antigen-binding portion according to claim 2 that is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody.

9. The antibody or antigen-binding portion according to claim 3 that is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody.

10. The antibody or antigen-binding portion according to claim 5 that is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody.

11. The antibody according to claim 1 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule.

12. The antibody according to claim 5 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule.

13. The antibody according to claim 3 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule.

14. The antibody according to claim 5 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule.

15. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 1 and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 5 and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 3 and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 5 and a pharmaceutically acceptable carrier.

19. A method for treating a tumor in a subject, comprising the step of administering to the subject an antibody or antigen-binding portion according to claim 1.

20. A method for treating a tumor in a subject, comprising the step of administering to the subject an antibody or antigen-binding portion according to claim 2.

21. A method for treating a tumor in a subject, comprising the step of administering to the subject an antibody or antigen-binding portion according to claim 3.

22. A method for treating a tumor in a subject, comprising the step of administering to the subject an antibody or antigen-binding portion according to claim 5.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.